PHP
MRNA icon

Parkman Healthcare Partners’s Moderna MRNA Stock Holding History

Parkman Healthcare Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$642K – 92
2020
Q2 		$642K Sell
10,000
-65,000
-87% -$3.56M 0.18% 75
2020
Q1 		$2.25M Buy
+75,000
New +$1.73M 1.04% 32

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parkman Healthcare Partners's MRNA Position: Q3 2020 in Review

Parkman Healthcare Partners sold out of Moderna (MRNA) in Q3 2020, closing a stake of 10,000 shares — an estimated $642K sold.

Parkman Healthcare Partners first reported a position in MRNA in Q1 2020 and held it in 2 quarters. The position peaked at $2.25M in Q1 2020. 548 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

  • Parkman Healthcare Partners reported no remaining Moderna position as of Q3 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 10,000 Moderna shares in Q3 2020, an estimated $642K.
  • Parkman Healthcare Partners first reported a position in Moderna in Q1 2020 and held it in 2 quarters.
  • Parkman Healthcare Partners's Moderna position peaked at $2.25M in Q1 2020.
  • 548 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on Parkman Healthcare Partners's 13F filing for Q3 2020, filed 13 Nov 2020.